Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.

Saved in:
Bibliographic Details
Title: Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.
Authors: Vitorino P; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA. Electronic address: philip.vitorino@abbvie.com., Chuang CH; AMGEN, 1120 Veterans Boulevard, South San Francisco, CA 94087, USA., Iannello A; Actym Therapeutics, 626 Bancroft Way Suite A, Berkeley, CA 94710, USA., Zhao X; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA., Anderson W; Notable Labs, 320 Hatch Drive, Foster City, CA 94404, USA., Ferrando R; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA., Zhang Z; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA., Madhavan S; UNITY Biotechnology, 285 E Grand Ave, South San Francisco, CA 94080, USA., Karsunky H; Deep Valley Labs, 3031 Tisch Way 605, San Jose, CA 95128, USA., Saunders LR; Everest Detection, 409 Illinois Street, San Francisco, CA 94158, USA.
Source: Translational oncology [Transl Oncol] 2021 Jan; Vol. 14 (1), pp. 100883. Date of Electronic Publication: 2020 Oct 15.
Publication Type: Journal Article
Journal Info: Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1936-5233
DOI:10.1016/j.tranon.2020.100883